Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD19-directed CAR-T in R/R B Cell Malignancy
NCT02537977Phase 2Unknown
- Sponsor
- Tongji Hospital
- Start
- Jul 2015
- Primary completion
- Jun 2020
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of CD19-directed CAR-T cells in leukemia, lymphoma, sponsored by Tongji Hospital. Status: unknown.
02
Drugs
CD19-directed CAR-T cells
03
Conditions
leukemialymphoma
Beyond the preview
Go deeper on NCT02537977.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02537977.